Abstract
Polycystic ovary syndrome (PCOS) is a heterogeneous syndrome of reproductive and metabolic derangements. The combination of anovulation and hyperandrogenism signifies the classic form of PCOS which displays the adverse metabolic phenotype of the syndrome. This phenotype includes visceral obesity and insulin resistance as well as a constellation of other traditional cardiovascular risk factors, mainly low grade inflammation, disturbances of glucose metabolism and dyslipidemia. The resultant increased risk for cardiovascular disease may affect not only obese but also lean women with classic PCOS. The mechanisms underlying the increased cardiovascular risk in the context of PCOS may include not only metabolic aberrations, but also hormonal factors, in particular hyperandrogenemia. However, the consequences in terms of CV morbidity remain questionable due to the difficulties in conducting long-term, prospective studies aimed at identifying potential late-arriving clinical outcomes.
Keywords: PCOS, hyperandrogenism, cardiovascular, metabolism, inflammation.
Current Pharmaceutical Design
Title:Structural, Biochemical and Non-Traditional Cardiovascular Risk Markers in PCOS
Volume: 19 Issue: 32
Author(s): Charikleia Christakou and Evanthia Diamanti-Kandarakis
Affiliation:
Keywords: PCOS, hyperandrogenism, cardiovascular, metabolism, inflammation.
Abstract: Polycystic ovary syndrome (PCOS) is a heterogeneous syndrome of reproductive and metabolic derangements. The combination of anovulation and hyperandrogenism signifies the classic form of PCOS which displays the adverse metabolic phenotype of the syndrome. This phenotype includes visceral obesity and insulin resistance as well as a constellation of other traditional cardiovascular risk factors, mainly low grade inflammation, disturbances of glucose metabolism and dyslipidemia. The resultant increased risk for cardiovascular disease may affect not only obese but also lean women with classic PCOS. The mechanisms underlying the increased cardiovascular risk in the context of PCOS may include not only metabolic aberrations, but also hormonal factors, in particular hyperandrogenemia. However, the consequences in terms of CV morbidity remain questionable due to the difficulties in conducting long-term, prospective studies aimed at identifying potential late-arriving clinical outcomes.
Export Options
About this article
Cite this article as:
Christakou Charikleia and Diamanti-Kandarakis Evanthia, Structural, Biochemical and Non-Traditional Cardiovascular Risk Markers in PCOS, Current Pharmaceutical Design 2013; 19 (32) . https://dx.doi.org/10.2174/1381612811319320011
DOI https://dx.doi.org/10.2174/1381612811319320011 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Strict Adherence to Guidelines in Decision Making for Coronary Angiography in Patients Who have Survived a Q Wave Myocardial Infarction; 2-Year Outcome in a Greek Population
Vascular Disease Prevention (Discontinued) Plasminogen Activator Inhibitor-1
Current Medicinal Chemistry Medical Treatment of Peripheral Arterial Disease: Current Concepts and Future Options
Vascular Disease Prevention (Discontinued) Fetal Undernutrition and the Programming of Blood Pressure
Current Nutrition & Food Science Application of Hematopoietic Cells to Therapeutic Angiogenesis
Current Pharmaceutical Design Pathophysiology of Atherosclerosis: The Role of Inflammation
Current Pharmaceutical Design Total Polyphenols and Bioactivity of Seeds and Sprouts in Several Legumes
Current Pharmaceutical Design The Pathophysiological Basis of Carotid Baroreceptor Stimulation for the Treatment of Resistant Hypertension
Current Vascular Pharmacology Prothrombotic Potential of NSAID in Ischemic Heart Diesase
Mini-Reviews in Medicinal Chemistry GRK2 at the Control Shaft of Cellular Metabolism
Current Pharmaceutical Design Nuclear Imaging of Post-infarction Inflammation in Ischemic Cardiac Diseases - New Radiotracers for Potential Clinical Applications
Current Radiopharmaceuticals Role of Curcumin in Modulating Plasma PON1 Arylesterase Activity and Susceptibility to LDL Oxidation in Oxidatively Challenged Wistar Rats
Letters in Drug Design & Discovery Apolipoprotein B Antisense Inhibition -Update on Mipomersen
Current Pharmaceutical Design Regulation of Apolipoprotein B by Natural Products and Nutraceuticals: A Comprehensive Review
Current Medicinal Chemistry Predictors of Ominous Outcome in Infants who Undergo Cardiac Surgery and Cardiopulmonary By-Pass: S100B Protein
CNS & Neurological Disorders - Drug Targets Use of Diuretics in Women for Management of Hypertension
Current Hypertension Reviews Current and Experimental Antibody-Based Therapeutics: Insights, Breakthroughs, Setbacks and Future Directions
Current Molecular Medicine Studies on Growth Kinetics of Serratia marcescens VITSD2 and Optimization of Fermentation Conditions for Serratiopeptidase Production
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Rosuvastatin and Diabetes: When the Evidences Talk
Cardiovascular & Hematological Agents in Medicinal Chemistry AMPK Activators as Novel Therapeutics for Type 2 Diabetes
Current Topics in Medicinal Chemistry